课题基金 / 基金详情

项目摘要

项目成果

Kevin Wiehe的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 我们最近已经成功地设计出能广泛中和HIV的免疫原。 抗体(BNAb)前体具有高亲和力,在免疫动物中扩增这些B细胞,并选择关键 对中和广度的发展至关重要的体细胞超突变。尽管前景看好,但 在漫长而复杂的进化道路上,进展仅限于第一步,就像bNAbs典型的 有大量的体细胞超突变。虽然只需要这些突变的一个子集 获得广度,尚不清楚哪些突变代表了环境识别的共同特征 可作为免疫原靶点的不同bNAb谱系。识别常见的成熟事件 针对相同bNAb表位的多个谱系共享的bNab发展对于 针对不同bNAb前体的疫苗设计策略。曾经的血统来自不同的起点 点位是参与并扩大与启动免疫原,增强免疫原将需要引导他们的 成熟,以获得广泛认可的组成部分。共享识别特征的标识为 只有通过比较以相同表位为靶点的一大组bNAb谱系才有可能。通过我们的电流 HIVRAD,我们已经证明了用于免疫原设计的灵长类bNAb B细胞谱系的一个来源可以是Shiv- 感染恒河猴(RMS)。我们已经证明,感染SHIV的RMS中有六分之一正在进行 以产生bNAb反应。这些反应中超过三分之一是针对V3-葡聚糖表位的, BNAbs在人类感染中最常见的靶点。V3糖链bNAb的结构测定 从感染SHV的RM中分离到的病毒与人类V3糖蛋白bNAb有惊人的相似之处,表明 V3糖链表位识别的收敛进化。因此,我们现在有了一个可靠地诱导V3的系统 糖链bNAbs可以为免疫原的设计提供信息,该免疫原能诱导针对V3糖链表位的bNAb。The the the 项目3的中心假设是,bNAb谱系识别V3糖链的方式存在共性 表位,免疫原可以被设计成为这些共享识别特征进行选择,当 联合使用序贯免疫方案将产生bNAbs。在目标1中,我们将确定常见的 新城疫病毒与人感染诱导的V3糖链表位识别的共同机制 BNAbs用于定义使用B细胞谱系追踪和快速结构的免疫原设计模板 决心。在目标2中,我们将设计能够激活恒河猴多个V3糖链谱系的免疫原 人类使用了一种新的设计目标,即首先选择具有长CDRH3的B细胞。在《目标3》中,我们将使用病毒 在哺乳动物细胞表面展示中作为环状病毒文库变异体来源的SHV感染猴子的测序 设计增强免疫原,在V3糖蛋白bNAb识别中选择共享成熟事件。项目 3将通过产生免疫原和增强免疫原来影响该领域,这些免疫原在RMS中进行测试,将导致疫苗 能够在人类身上引发bNAb的候选人。
英文摘要
PROJECT SUMMARY We have demonstrated recent success in designing immunogens that can bind HIV broadly neutralizing antibodies (bNAb) precursors with high affinity, expand these B cells in immunized animals, and select for key somatic hypermutations essential for the development of neutralization breadth. Although promising, the progress has been limited to just the first steps along long and complex evolutionary pathways as bNAbs typically have extensive numbers of somatic hypermutation. While only a subset of these mutations is necessary for acquisition of breadth, it is unclear which mutations represent shared features of Env recognition between different bNAb lineages that can be targeted with immunogens. Identifying the common maturational events in bNAb development shared by multiple lineages that target the same bNAb epitope is of critical importance for vaccine design strategies that target a diverse pool of bNAb precursors. Once lineages from diverse starting points are engaged and expanded with priming immunogens, boosting immunogens will need to direct their maturation to acquire the components of broad recognition. The identification of shared recognition features is only possible by comparing a large set of bNAb lineages that target the same epitope. Through our current HIVRAD, we have shown one source of primate bNAb B cell lineages for immunogen design can be SHIV- infected rhesus macaques (RMs). We have demonstrated that one in six RMs infected by SHIVs have gone on to generate bNAb responses. Over one third of these responses have been targeted to the V3-glycan epitope, the most common site targeted by bNAbs in human infection. Structural determination of a V3 glycan bNAb isolated from a SHIV infected RM revealed striking similarities to a human V3 glycan bNAb indicating remarkable convergent evolution of V3 glycan epitope recognition. Thus, we now have a system for reliably inducing V3 glycan bNAbs that can inform the design of immunogens that elicit bNAbs targeting the V3 glycan epitope. The central hypothesis of Project 3 is that commonalities exist in how bNAb lineages recognize the V3 glycan epitope, and that immunogens can be designed to select for these shared recognition features which when combined in a sequential immunization regimen will elicit bNAbs. In Aim 1, we will identify the common mechanisms of V3 glycan epitope recognition shared between SHIV and human infection-induced V3 glycan bNAbs to define templates for immunogen design using B cell lineage tracing and a rapid structural determination. In Aim 2, we will design immunogens that can prime multiple V3 glycan lineages in rhesus and humans using a novel design goal of selecting first for B cells with long CDRH3s. In Aim 3, we will use viral sequencing of SHIV infected monkeys as a source for Env library variants in mammalian cell surface display to design boosting immunogens that select for shared maturational events in V3 glycan bNAb recognition. Project 3 will impact the field by generating prime and boosting immunogens, tested in RMs, that will lead to vaccine candidates capable of eliciting bNAbs in humans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project 2: PanbetaCoV protein vaccine design
  • 批准号:
    10327524
  • 项目类别:
  • 资助金额:
    $421.74万
  • 财政年份:
    2021
  • 负责人:
    Kevin Wiehe
  • 依托单位:
Project 2: PanbetaCoV protein vaccine design
  • 批准号:
    10842503
  • 项目类别:
  • 资助金额:
    $282.88万
  • 财政年份:
    2021
  • 负责人:
    Kevin Wiehe
  • 依托单位:
Immunogen design to elicit polyclonal bNAb responses to the V3 glycan supersite
  • 批准号:
    10370985
  • 项目类别:
  • 资助金额:
    $90.11万
  • 财政年份:
    2017
  • 负责人:
    Kevin Wiehe
  • 依托单位:
海外基金